In a double-blind, randomized and placebo-controlled trial, adjuvant allopurinol improved symptoms of mania in in-patients suffering from bipolar disorder

European Neuropsychopharmacology

Volumn 24, Issue 8, 2014, Pages 1210-1221

  Jahangard, Leila ^a   Soroush, Sara ^a   Haghighi, Mohammad ^a   Ghaleiha, Ali ^a   Bajoghli, Hafez ^b,c   Holsboer Trachsler, Edith ^d   Brand, Serge ^d,e  

^a HAMADAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c MAHIDOL UNIVERSITY   (Thailand)

^d UNIVERSITY OF BASEL   (Switzerland)

^e UNIVERSITY OF BASEL   (Switzerland)

Author keywords

Allopurinol; Bipolar disorders; Double blind; Mania; Placebo controlled trial

Indexed keywords

ALLOPURINOL; PLACEBO; URIC ACID; VALPROIC ACID; ENZYME INHIBITOR;

ADJUVANT THERAPY; ADULT; AGITATION; ARTICLE; BIPOLAR I DISORDER; CLINICAL GLOBAL IMPRESSION SCALE; CONSTIPATION; CONTROLLED STUDY; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DIARRHEA; DISEASE SEVERITY; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG SAFETY; DYSPEPSIA; FEMALE; GASTROINTESTINAL SYMPTOM; GROUP DYNAMICS; HEADACHE; HUMAN; HYPERACTIVITY; MAJOR CLINICAL STUDY; MALE; MANIA; NERVOUSNESS; NEUROLOGIC DISEASE; PAIN; PALLIATIVE THERAPY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REMISSION; SIDE EFFECT; SLEEP DISORDER; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; URIC ACID BLOOD LEVEL; XEROSTOMIA; YOUNG MANIA RATING SCALE; ANALYSIS OF VARIANCE; BIPOLAR DISORDER; MIDDLE AGED; PSYCHOLOGICAL RATING SCALE; TIME;

ADULT; ALLOPURINOL; ANALYSIS OF VARIANCE; BIPOLAR DISORDER; DOUBLE-BLIND METHOD; ENZYME INHIBITORS; FEMALE; HUMANS; MALE; MIDDLE AGED; PSYCHIATRIC STATUS RATING SCALES; TIME FACTORS;

EID: 84904958721     PISSN: 0924977X     EISSN: 18737862     Source Type: Journal    
DOI: 10.1016/j.euroneuro.2014.05.013     Document Type: Article

References (29)

1. Akhondzadeh S., Milajerdi M.R., Amini H., Tehrani-Doost M. Allopurinol as an adjunct to lithium and haloperidol for treatment of patients with acute mania: a double-blind, randomized, placebo-controlled trial. Bipolar Disord. 2006, 8:485-489.
2. American Psychiatric Association Diagnostic and Statistical Manual of Mental Disorders 2000, American Psychiatric Association, Washington, DC. 4 ed.
3. Barrera C.M., Hunter R.E., Dunlap W.P. Hyperuricemia and locomotor activity in developing rats. Pharmacol. Biochem. Behav. 1989, 33(2):367-369.
4. Cade J. Lithium salts in the treatment of psychotic excitement. Med. J. Aust. 1949, 2:349-352.
5. Chung K.H., Huang C.C., Lin H.C. Increased risk of gout among patients with bipolar disorder: a nationwide population-based study. Psychiatry Res. 2010, 180:147-150.
6. De Berardis D., Conti C.M., Campanella D., Carano A., Di Giuseppe B., Valchera A., Tancredi L., Serroni N., Pizzorno A.M., Fulcheri M., Gambi F., Sepede G., Moschetta F.S., Salerno R.M., Ferro F,M. Evaluation of plasma antioxidant levels during different phases of illness in adult patients with bipolar disorder. J. Biol. Regul. Homeost. Agents 2008, 22:195-200.
7. Fan A., Berg A., Bresee C., Glassman L.H., Rapaport M.H. Allopurinol augmentation in the outpatient treatment of bipolar mania: a pilot study. Bipolar Disord. 2012, 14:206-210.
8. Gardner H.H., Kleinman N.L., Brook R.A., Rajagopalan K., Brizee T.J., Smeeding J.E. The economic impact of bipolar disorder in an employed population from an employer perspective. J. Clin. Psychiatry 2006, 67:1209-1218.
9. Guy W. ECDEU Assessment for Psychopharmacology, Revised Edition 1976, NIMH Publication, Rockville, MD.
10. Kamalinia G., Brand S., Ghaeli P., Abedi N., Bajoghli H., Sharifi V., Zahiroddin A., Amini M., Rouini M.,R., Holsboer-Trachsler E., Mohammadpoor A.,H. Serum levels of sodium valproate in patients suffering from bipolar disorders: comparing acute and maintenance phases of mania. Pharmacopsychiatry 2013, 46:83-87.
11. Kilbane E.J., Gokbayrak N.S., Galynker I., Cohen L., Tross S. A review of panic and suicide in bipolar disorder: does comorbidity increase risk?. J. Affect Disord. 2009, 115:1-10.
12. Kraepelin E. 1913. Manic-depressive insanity and paranoia (R. Mary Barclay, Trans.), In: George M., Robertson E., Livingstone S., Edinburgh (Eds.), Text-Book of Psychiatry: Endogenous Dementias, vol. iii, part ii, eighth German edition, Chicago Medical Book Company, Chicago, 1921 ([Übersetzung von Kapitel XI "Das manisch-depressive Irresein" aus 1913a und von Kapitel XIV "Die Verrücktheit (Paranoia)" aus 1915a in englischer Sprache]. Psychiatrie. Ein Lehrbuch für Studierende und Ärzte. Achte, vollständig umgearbeitete Auflage. III. Band. Klinische Psychiatrie. II. Teil. Barth Verlag, Leipzig. [vgl. 1909a, 1910a, 1915a].
13. Lara D.R., Dall'Igna O.P., Ghisolfi E.S. Brunstein MG.Involvement of adenosine in the neurobiology of schizophrenia and its therapeutic implications. Prog. Neuropsychopharmacol. Biol. Psychiatry 2006, 2006:17-29.
14. Machado-Vieira R., Salvadore G., DiazGranados N., Ibrahim L., Latov D., Wheeler-Castillo C., Baumann J., Henter I.D., Zarate C.A. New therapeutic targets for mood disorders. Sci. World J. 2010, 10:713-726.
15. Machado-Vieira R. Purinergic system in the treatment of bipolar disorder: uric acid levels as a screening test in mania. J. Clin. Psychopharmacol. 2012, 32(5):735-736. ([PubMed: 22926622]).
16. Machado-Vieira R., Lara D.R., Souza D.O., Kapczinski F.T. Therapeutic efficacy of allopurinol in mania associated with hyperuricemia. J. Clin. Psychopharmacol. 2001, 21:621-622.
17. Machado-Vieira R., Soares J.C., Lara D.R., Luckenbaugh D.A., Busnello J.V., Marca G., Cunha A., Souza D.O., Zarate C.A., Kapczinski F.A. Double-blind, randomized, placebo-controlled 4-week study on the efficacy and safety of the purinergic agents allopurinol and dipyridamole adjunctive to lithium in acute bipolar mania. J. Clin. Psychiatry 2008, 69:1237-1245.
18. Machado-Vieira R., Zarate C.A. Proof of concept trials in bipolar disorder and major depressive disorder: a translational perspective in the search for improved treatments. Depress Anxiety 2011, 28:267-281.
19. Nayak G.H., Prentice H.M., Milton S.L. Neuroprotective signaling pathways are modulated by adenosine in the anoxia tolerant turtle. J. Cereb. Blood Flow Metab. 2011, 31:467-475.
20. Perlis R.H., Ostacher M.J., Patel J.K., Marangell L.B., Zhang H., Wisniewski S.R., Ketter T.A., Miklowitz D.J., Otto M.W., Gyulai L., Reilly-Harrington N.A., Nierenberg A.A., Sachs G.S., Thase M.E. Predictors of recurrence in bipolar disorder: primary outcomes from the systematic treatment enhancement program for bipolar disorder (STEP-BD). Am. J. Psychiatry 2006, 163. (217-124).
21. Plante D.T., Winkelman J.W. Sleep disturbance in bipolar disorder: therapeutic implications. Am. J. Psychiatry 2008, 165:830-843.
22. Porkka-Heiskanen T., Kalinchuk A.V. Adenosine, energy metabolism and sleep homeostasis. Sleep Med. Rev. 2011, 15:123-135.
23. Salvadore G, Viale CI, et al. Increased uric acid levels in drug-naïve subjects with bipolar disorder during a first manic episode. Prog. Neuropsychopharmacol. Biol. Psychiatry 2010, 34(6):819-821. ([PubMed: 20206224]).
24. Sanches M., Newberg A.R., Soares J.C. Emerging drugs for bipolar disorder. Exp. Opin. Emerg. Drugs 2010, 15:453-466.
25. Sheehan D.V., Lecrubier Y., Sheehan K.H., Amorim P., Janavs J., Weiller E., Hergueta T., Baker R., Dunbar G.,C. The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J. Clin. Psychiatry 1998, 59(Suppl. 20):S22-S33.
26. Stone T.W., Ceruti S., Abbracchio M.P. Adenosine receptors and neurological disease: neuroprotection and neurodegeneration. Handbook of Experimental Pharmacology 2009, 193:535-587.
27. Togha M., Akhondzadeh S., Motamedi M., Ahmadi B., Razeghi S. Allopurinol as adjunctive therapy in intractable epilepsy: a double blind and placebo-controlled trial. Arch. Med. Res. 2007, 38:313-316.
28. Weiser M., Burshtein S., Gershon A.A., Marian G., Vlad N., Grecu I.G., Tocari E., Tiugan A., Hotineanu M., Davis J.M. Allopurinol for mania: a randomized trial of allopurinol versus placebo as add-on treatment to mood stabilizers and/or antipsychotic agents in manic patients with bipolar disorder. Bipolar Disord 2014, 16:441-447.
29. Young R.C., Biggs J.T., Ziegler V.E., Meyer D.A. A rating scale for mania: reliability, validity and sensitivity. Br. J. Psychiatry 1978, 133:429-435.